Validation of a French version of a compliance questionnaire for rheumatology
Official title: Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology): Specific Tool for Evaluation of Observance of Rheumatology Treatment
Run by Centre Hospitalier Universitaire de Nīmes · NCT03642795 · Data updated 2026-11-12
This study is testing a French version of a questionnaire to see how well it helps patients with rheumatoid arthritis understand and follow their methotrexate treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Drugs / interventions | Methotrexate |
| Locations | 4 sites (Bordeaux and 3 other locations) |
| Status | Recruiting |
| Started | June 23, 2022 |
| Main results expected | March 2029 |
| Study ends | March 2029 |
| Registry record updated | December 3, 2025 |
| Trial ID | NCT03642795 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are French-speaking adults aged 18 and older with rheumatoid polyarthritis who have been on stable methotrexate treatment.
✕Probably not a fit
Patients who are not fluent in French or those who are currently participating in other interventional studies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop and validate a French language version of the Compliance Questionnaire Rheumatology (CQR) to be used in French-speaking rheumatology services. It involves collecting data from patients with rheumatoid polyarthritis who have been stable on methotrexate treatment. Participants will complete the questionnaire to assess their compliance with treatment. The results will help ensure that the questionnaire is culturally and linguistically appropriate for French-speaking populations.
Why it matters
Potential benefit: If successful, this study could improve the assessment of treatment compliance among French-speaking patients with rheumatoid polyarthritis.
How similar studies have gone: Other studies have successfully validated similar compliance questionnaires in different languages, indicating a positive precedent for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient is at least 18 years old * The patient has rheumatoid polyarthritis as defined by the ACR-EULAR 2010 criteria, treated orally or subcutaneously with MTX for at least 3 months with a stable (unchanged) dosage for at least 1 month, and a stable (unchanged) route of administration for at least 1 month. And no planned change in Methotrexate intake at least until the second study visit. Other treatments at the same time are authorized Exclusion Criteria: * The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * The subject has a contraindication to taking methotrexate (including a patient with a desire to become pregnant).
Where it's running
-
CHU Nimes
Nîmes, France Recruiting -
CHU Bordeaux
Bordeaux, France Not yet recruiting -
CHRU Montpellier
Montpellier, France Not yet recruiting -
CHU Toulouse
Toulouse, France Not yet recruiting
Study contacts
- Study coordinator: Cécile Gaujoux Viala, MD
- Email: cecile.gaujoux.viala@chu-nimes.fr
- Phone: 04 66 68 31 20
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Collection of biological samples for diagnosing rare neurological diseases
This study is collecting blood and spinal fluid samples from people with rare neurological diseases to see if they can find new markers that help diagnose these conditions more accurately.
-
Post-marketing surveillance of a femoral stem prosthesis for hip replacement
This study is tracking how well a specific hip replacement device works and its safety in people aged 18 to 75 who are having hip surgery for different joint problems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.